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Final Agenda: 
9.00-9.30 Registration and coffee 
9.30-12.45 Session 1: Challenges and potential solutions for processing of viral vectors 
9.30-10.00 Viral Vector workflow overview: From construct to USP to DSP 
Anandita Seth, Head of Research and Technology, Viral Therapy, Lonza 
10.00-10.30 Insights into adeno-associated virus processing 
Hanna Lesch, Gene Therapy Unit Director, Kuopio Centre for Gene & Cell Therapy (KCT) 
10.30-11.00 Scaling up lentiviral vector production from Cell Factories to disposable 
bioreactor: development and optimization of upstream and downstream process steps 
Luca Crippa, Downstream Vector Development Supervisor, MolMed 
11.00-11.20 Coffee break 
11.20-12.50 Activity: Assessing the impact of process related decisions on 
manufacturability of viral vectors  
12.50-13.30 Lunch & Networking 
13.30-16.50 Session 2: Next generation gene therapies: Continuous bioprocessing  
13.30-14.00 Continuous bioprocessing for viral vectors -upstream processing 
Sven Ansorge, Research Officer, National Research Council Canada 
14.00-14.20 Technology Transfer of Cell and Gene Therapy Products into a new GMP 
Facility : Success Factors and Key Challenges 
LiYing Yang, Head of MSAT, Lonza 
14.20-16.10 Activity: In groups join the discussion with your table lead. Table leads are:  
1. Damian Marshall, Director of New and Enabling Technologies, CGT Catapult 
2. Peter Jones, Head of Operational Strategy, Oxford Biomedica 
3. David Pollard, Head of New Materials & Components, Sartorius Stedim 
4. Sven Ansorge, Research Officer, National Research Council Canada 
5. LiYing Yang, Head of MSAT, Lonza 
6. Luca Crippa, Downstream Vector Development Supervisor, MolMed 
7. Hanna Lesch, Gene Therapy Unit Director, Kuopio Centre for Gene and Cell Therapy (KCT) 
16.10-16.50 Conclusions from the discussions 
16.50-17.00 Wrap-up and closure 
